Understanding m6A changes in chromophobe renal cell carcinoma and predicting patient outcomes survival

Zhigang Chen,Junbo Yang,Wei Zhang,Yang Qian,Nan Zhang,Zixin Chen,Min Lu,Liyuan Ge,Cheng Liu,Xiaojun Tian,Guifang Jia,Lulin Ma,Baoguo Li
DOI: https://doi.org/10.1186/s12885-024-12956-6
IF: 4.638
2024-09-29
BMC Cancer
Abstract:N6-methyladenosine (m 6 A) is a prevalent mRNA modification known for its implications in various cancer types, yet its role in chromophobe renal cell carcinoma (chRCC) remains largely unexplored. In this study, we performed m6A-SEAL-seq and RNA-seq analyses on tissues from three chRCC subjects, aiming to uncover m 6 A alterations in chRCC. Our findings revealed reduced expression levels of four m 6 A regulators in chRCC tissues and highlighted differences in m 6 A levels compared to normal tissues. Furthermore, we identified specific genes and cancer-related pathways affected by these differences, including notable candidates like NOTCH1 and FGFR1, implicated in chRCC development. Additionally, we developed a predictive model based on the expression level of m 6 A associated genes, demonstrating promising prognostic capabilities for patient survival prediction. Overall, our study provides valuable insights into the role of m 6 A in chRCC and its potential as a prognostic indicator.
oncology
What problem does this paper attempt to address?